Translational Development Acquisition Corp. (TDACU) Prices $150M IPO

Translational Development Acquisition Corp. (NASDAQ: TDACU) announced the pricing of its $150 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “TDACU”, Monday, December 23, 2024.

The new SPAC intends to take a generalist approach in searching for a business combination, but intend to focus on industries that complement the management team’s background.

Translational Development Acquisition Corp.’s sponsor team is led by Chief Executive Officer and Director Michael B. Hoffman, and Chief Financial Officer Avanindra C. Das.

E. Premkumar Reddy, Curtis T. Keith, Matthew A. Kestenbaum, and Christopher Jarratt will serve on its Board of Directors.

Total SPAC deal count for 2024 year-to-date is now 57. This offering is expected to close on Tuesday, December 24, 2024.

BTIG, LLC is acting as sole book-running manager for the offering. Venable LLP is serving as Issuer’s Counsel with Loeb & Loeb LLP serving as Underwriter’s Counsel. WithumSmith+Brown, PC serves as auditor. Continental Transfer & Trust Company is acting as trustee.